Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.
Structural Tailwinds
The cost of genomic sequencing has dropped from nearly $100mm per genome in 2002 to less than $1,000 in 2020. Adoption has continued to rise, as costs plummet (Source: National Human Genome Research Institute, Nov 2021).
Targeted Exposure
The ETF provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.
Capital at Risk. All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed.
ETF Summary
The Global X Genomics & Biotechnology UCITS ETF (GNOM LN) seeks to invest in
companies that potentially stand to benefit from further advances in the field
of genomic science, such as companies involved in gene editing, genomic
sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
ETF Objective
The Global X Genomics & Biotechnology UCITS ETF (GNOM LN) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics v2 Index.
Regulatory
SFDR Classification
Article 6
UCITS Compliant
Yes
ISA Eligibility
Yes
SIPP Eligibility
Yes
UK Reporting Status
Yes
Authorized Participants & Market Makers
Citigroup Global Markets,
DRW Europe BV,
Flow Traders BV,
GHCO LLP,
HSBC Bank PLC,
Jane Street Financial Ltd,
Mirae Asset Securities UK Ltd,
Societe Generale SA,
Susquehanna Intl Ltd, Virtu Financial Ireland Ltd, JP Morgan Securities PLC
Performance History
USD Accumulating
As of recent Month End & Quarter End (31 Mar 2026)
ETF
Index
Difference
1 Year
37.99%
38.52%
-0.53%
3 Years
-3.39%
-2.67%
-0.72%
Since Inception
-14.29%
-13.87%
-0.42%
Top Holdings
As of 28 Apr 2026
Net Assets (%)
Ticker
Name
Country
SEDOL
Market Price ($)
Shares Held
Market Value ($)
7.67
MRNA
MODERNA INC
US
BGSXTS3
47.14
33,742
1,590,597.88
7.00
ARWR
ARROWHEAD PHARMACEUTICALS IN
US
BYQBFJ8
70.13
20,686
1,450,709.18
6.61
PRAX
PRAXIS PRECISION MEDICINES I
US
BQ721R4
321.92
4,257
1,370,413.44
5.37
ILMN
ILLUMINA INC
US
2613990
126.92
8,770
1,113,088.40
4.62
GH
GUARDANT HEALTH INC
US
BFXC911
83.09
11,532
958,193.88
4.17
NTRA
NATERA INC
US
BYQRG48
200.17
4,323
865,334.91
4.15
VRTX
VERTEX PHARMACEUTICALS INC
US
2931034
430.14
1,998
859,419.72
4.13
BMRN
BIOMARIN PHARMACEUTICAL INC
US
2437071
53.30
16,071
856,584.30
3.97
BNTX
BIONTECH SE-ADR
US
BK6H543
102.06
8,064
823,011.84
3.47
TECH
BIO-TECHNE CORP
US
BSHZ3Q0
53.51
13,438
719,067.38
Trading Information
As of 28 Apr 2026
USD Accumulating (ISIN: IE00BM8R0N95)
Exchange
Trading Currency
Ticker
Listing Date
SEDOL
Net Asset Value (NAV)
Shares Outstanding
Net Assets
London Stock Exchange
USD
GNOM LN
04 Nov 2021
BP49D86
$8.01 (-1.60%)
2,590,000
$20,734,043.60
London Stock Exchange
GBP
GNOG LN
04 Nov 2021
BP49D97
--
--
--
Borsa Italiana
EUR
GNOM IM
18 Nov 2021
BP49DD1
--
--
--
Deutsche Börse Xetra
EUR
GN0M GY
11 Nov 2021
BP49DB9
--
--
--
SIX Swiss Exchange
CHF
GNOM SW
06 Dec 2021
BP49DC0
--
--
--
Trading Details
As of 28 Apr 2026
Primary Ticker
GNOM
Primary ISIN
IE00BM8R0N95
Bloomberg Index Ticker
SOLGNOM2
Number of Holdings
49
Index Provider
Solactive AG
Management Style
Physical - Full Replication - Passively Managed Index Tracking
